DK1432803T3 - Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas - Google Patents

Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas

Info

Publication number
DK1432803T3
DK1432803T3 DK02777726T DK02777726T DK1432803T3 DK 1432803 T3 DK1432803 T3 DK 1432803T3 DK 02777726 T DK02777726 T DK 02777726T DK 02777726 T DK02777726 T DK 02777726T DK 1432803 T3 DK1432803 T3 DK 1432803T3
Authority
DK
Denmark
Prior art keywords
metabolic
fragments
disorders
human
methods
Prior art date
Application number
DK02777726T
Other languages
Danish (da)
English (en)
Inventor
Ilya Chumakov
Oxana Guerassimenko
Original Assignee
Serono Genetics Inst Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Inst Sa filed Critical Serono Genetics Inst Sa
Application granted granted Critical
Publication of DK1432803T3 publication Critical patent/DK1432803T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02777726T 2001-10-05 2002-10-03 Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas DK1432803T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32772501P 2001-10-05 2001-10-05
PCT/IB2002/004598 WO2003050281A2 (en) 2001-10-05 2002-10-03 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity

Publications (1)

Publication Number Publication Date
DK1432803T3 true DK1432803T3 (da) 2008-03-10

Family

ID=23277766

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777726T DK1432803T3 (da) 2001-10-05 2002-10-03 Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas

Country Status (11)

Country Link
US (1) US7402393B2 (cg-RX-API-DMAC7.html)
EP (1) EP1432803B1 (cg-RX-API-DMAC7.html)
JP (1) JP4423038B2 (cg-RX-API-DMAC7.html)
AT (1) ATE380868T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002339678B2 (cg-RX-API-DMAC7.html)
CA (1) CA2461491A1 (cg-RX-API-DMAC7.html)
DE (1) DE60224064T2 (cg-RX-API-DMAC7.html)
DK (1) DK1432803T3 (cg-RX-API-DMAC7.html)
ES (1) ES2295415T3 (cg-RX-API-DMAC7.html)
IL (2) IL161233A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003050281A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509545B8 (en) 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Homotrimeric extended obg3 globular head and uses thereof
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
EP1548445A3 (en) * 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質aivを用いたi型糖尿病の治療法
US11213567B2 (en) * 2017-09-29 2022-01-04 L&C Bio Co., Ltd. ZAG-derived peptide and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9811465D0 (en) * 1998-05-29 1998-07-29 Tisdale Michael J Glycoproteins having lipid mobilising properties and therapeutic applications thereof
BR0107626A (pt) * 2000-01-14 2002-10-15 Genset Sa Cabeças globulares de obg3 e usos destes para diminuir a massa corporal
CA2462588A1 (en) * 2001-10-12 2003-04-24 Genset S.A. Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof

Also Published As

Publication number Publication date
AU2002339678B2 (en) 2007-10-25
JP4423038B2 (ja) 2010-03-03
DE60224064T2 (de) 2008-11-20
DE60224064D1 (de) 2008-01-24
AU2002339678B8 (en) 2003-06-23
US7402393B2 (en) 2008-07-22
US20070054845A1 (en) 2007-03-08
IL161233A0 (en) 2004-09-27
AU2002339678A1 (en) 2003-06-23
CA2461491A1 (en) 2003-06-19
EP1432803B1 (en) 2007-12-12
JP2005511088A (ja) 2005-04-28
IL161233A (en) 2010-05-17
EP1432803A2 (en) 2004-06-30
WO2003050281A2 (en) 2003-06-19
WO2003050281A3 (en) 2003-12-04
ATE380868T1 (de) 2007-12-15
ES2295415T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
DE60135439D1 (de) Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
NO20056049L (no) Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
NO20055731L (no) Cannabinoide reseptorligander og deres anvendelse
ATE424416T1 (de) Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
ATE356607T1 (de) Verwendung von nativem zein zur verbesserung des haarzustandes und mittel
DE50312145D1 (de) Vorrichtung zur behandlung von frakturen des femur
WO2005046583A3 (en) Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
ATE471717T1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
NO20055741L (no) Nye kjemiske forbindelser
Langdahl New treatments of osteoporosis
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
ATE304854T1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE380868T1 (de) Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit
MXPA05009193A (es) Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
DE602004027923D1 (de) Zusammensetzung mit notoginseng radix extrakt zur prävention und behandlung von arthritis als wirksamer inhaltsstoff
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
FR2837495B1 (fr) Installation modulable, demontable, transportable, pour le traitement par thermolyse et pour la valorisation energetique des dechets
ATE410235T1 (de) Behandlung von ballastwasser
WO2002060466A3 (en) Gssp3 polynucleotides and polypeptides and uses thereof
ATE410415T1 (de) Neue verbindungen
EA200401395A1 (ru) Способ лечения или профилактики микробных заболеваний ногтя субъекта (варианты), композиция для местного нанесения на ноготь и способ ее получения
WO2003051911A3 (en) Gmg-5 polynucleotides and polypeptides and uses thereof
WO2003095485A3 (en) Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders